HIV-1 drug resistance in Thailand: Before and after National Access to Antiretroviral Program

Journal of Clinical Virology

Volumn 34, Issue 4, 2005, Pages 272-276

  Sutthent, Ruengpung ^a   Arworn, Daungnapa ^a   Kaoriangudom, Surapol ^b   Chokphaibulkit, Kulkanya ^c   Chaisilwatana, Pongsakdi ^c   Wirachsilp, Piyanot ^a   Thiamchai, Vipa ^b   Sirapraphasiri, Thaweesarp ^b   Tanprasertsuk, Sombat ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Access; Antiretroviral; Drug resistance; HIV 1; Thailand

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EDETIC ACID; NEVIRAPINE; POL PROTEIN; THYMIDINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD SAMPLING; CHEMOPROPHYLAXIS; CODON; CONTROLLED STUDY; DRUG MONITORING; HEALTH CARE ACCESS; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENES, POL; GOVERNMENT PROGRAMS; HEALTH SURVEYS; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; THAILAND; THYMIDINE; TREATMENT OUTCOME;

EID: 27744468980     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2005.02.014     Document Type: Article

References (10)

1. Bureau of Epidemiology, Department of Diseases Control, Ministry of Public Health, Thailand, 2003.
2. The Thai Working Group on HIV/AIDS projection. Projection for HIV/AIDS in Thailand: 2000-2020. Division of AIDS, Department of Communicable Disease Control, Ministry of Public Health, 2000.
3. C.A. Boucher, E. O'Sullivan, J.W. Mulker, C. Ramautarsing, P. Kellam, and G. Darby Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects J Infect Dis 165 1992 105 110
4. C. de Mendoza, O. Gallego, and V. Soriano Mechanisms of resistance to antiretroviral drugs-clinical implications AIDS Rev 4 2002 64 82
5. J. Goudsmit, R.A. de Ronde, E. de Roeij, and R. Boer Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulation differing at reverse transcriptase codons 41 and 215 J Virol 71 1997 4479 4484
6. D.R. Kuritzkes, R.L. Bassett, and R.K. Young Rate of emergence of thymidine analogue resistance mutations in HIV-1 reverse transcriptase selected by stavudine or zidovudine-based regimens in treatment-naïve patients Antivir Ther 7 2002 S31
7. J. Lange A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm Antivir Ther 6 Suppl. 3 2001 45 54
8. B.A. Larder, S. Bloor, and S.D. Kemp A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance Antimicrob Agents Chemother 43 1999 1961 1967
9. V. Soriano, and C. de Mendoza Genetic mechanisms of resistance to NRTI and NNRTI HIV Clin Trials 3 2002 237 248
10. P. Kellam, C.A. Boucher, and B.A. Larder Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine Proc Natl Acad Sci USA 89 1992 134 138